share_log

6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer

6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer

6-K:Jemperli Plus化疗的申请已接受欧洲药品管理局的审查,以便将使用范围扩大到所有原发性晚期或复发性子宫内膜癌患者
美股sec公告 ·  06/24 06:15
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息